TWI870839B - 可用於降尿酸的化合物 - Google Patents

可用於降尿酸的化合物 Download PDF

Info

Publication number
TWI870839B
TWI870839B TW112115878A TW112115878A TWI870839B TW I870839 B TWI870839 B TW I870839B TW 112115878 A TW112115878 A TW 112115878A TW 112115878 A TW112115878 A TW 112115878A TW I870839 B TWI870839 B TW I870839B
Authority
TW
Taiwan
Prior art keywords
group
alkyl
substituted
compound
nitrile
Prior art date
Application number
TW112115878A
Other languages
English (en)
Chinese (zh)
Other versions
TW202342456A (zh
Inventor
東方 史
傅長金
楊豔
李海明
袁承詣
Original Assignee
大陸商杭州新元素藥業有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商杭州新元素藥業有限公司 filed Critical 大陸商杭州新元素藥業有限公司
Publication of TW202342456A publication Critical patent/TW202342456A/zh
Application granted granted Critical
Publication of TWI870839B publication Critical patent/TWI870839B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112115878A 2022-04-27 2023-04-27 可用於降尿酸的化合物 TWI870839B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022104569393 2022-04-27
CN202210456939 2022-04-27

Publications (2)

Publication Number Publication Date
TW202342456A TW202342456A (zh) 2023-11-01
TWI870839B true TWI870839B (zh) 2025-01-21

Family

ID=87872273

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112115878A TWI870839B (zh) 2022-04-27 2023-04-27 可用於降尿酸的化合物

Country Status (6)

Country Link
US (1) US20250282753A1 (https=)
EP (1) EP4516781A4 (https=)
JP (1) JP7792730B2 (https=)
CN (1) CN116715633B (https=)
TW (1) TWI870839B (https=)
WO (1) WO2023208108A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119241538A (zh) * 2024-09-30 2025-01-03 陕西科技大学 一类三唑并吡啶结构的化合物、合成方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201118077A (en) * 2009-10-07 2011-06-01 Lg Life Sciences Ltd Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
CN115160299A (zh) * 2021-04-29 2022-10-11 江苏新元素医药科技有限公司 一类黄嘌呤氧化酶抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336142T3 (es) * 2005-08-19 2010-04-08 Aventis Pharmaceuticals Inc. Combinacion de un agente hipnotico y un compuesto sustituido, con bis arilo y heteroarilo y aplicacion terapeutica del mismo.
JP5222561B2 (ja) * 2005-10-07 2013-06-26 キッセイ薬品工業株式会社 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
WO2010044403A1 (ja) 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 ５員環ヘテロアリール誘導体及びその医薬用途
CA2739058A1 (en) * 2008-10-15 2010-04-22 Kissei Pharmaceutical Co., Ltd. Fused heterocyclic derivative and use thereof for medical purposes
KR20100092909A (ko) * 2009-02-13 2010-08-23 주식회사 엘지생명과학 잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물
DK2669270T3 (en) * 2011-01-28 2018-02-26 Sato Pharma Indole-related compounds such as URAT1 inhibitors
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
CN105189476B (zh) 2013-03-29 2017-07-07 帝人制药株式会社 吡唑衍生物
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技（上海）有限公司 羧酸化合物及其制备方法和用途
KR20170105021A (ko) 2015-01-28 2017-09-18 아스테라스 세이야쿠 가부시키가이샤 피라진카르복사마이드 화합물의 제조 방법 및 그 합성 중간체
JP6873904B2 (ja) 2015-08-28 2021-05-19 Ils株式会社 キサンチンオキシダーゼ阻害剤
RU2733750C2 (ru) * 2015-09-02 2020-10-06 Саншайн Лейк Фарма Ко., Лтд. Производные карбоксизамещенных (гетеро)ароматических колец, способ их получения и применение
KR102109061B1 (ko) * 2015-09-10 2020-05-11 쟝쑤 애텀 바이오사이언스 앤드 파머수티컬 컴퍼니 리미티드 고요산혈증 또는 통풍을 치료 또는 예방하는 화합물
CN107759588B (zh) * 2016-08-19 2020-10-23 江苏新元素医药科技有限公司 一类苯基-(吡唑并[1,5-a]吡啶-3-基)甲酮衍生物
MX2021000887A (es) * 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CN116438175B (zh) * 2020-11-11 2025-07-22 南京明德新药研发有限公司 苯并脲环衍生物及其制备方法和应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201118077A (en) * 2009-10-07 2011-06-01 Lg Life Sciences Ltd Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
CN115160299A (zh) * 2021-04-29 2022-10-11 江苏新元素医药科技有限公司 一类黄嘌呤氧化酶抑制剂

Also Published As

Publication number Publication date
JP7792730B2 (ja) 2025-12-26
EP4516781A1 (en) 2025-03-05
CN116715633A (zh) 2023-09-08
CN116715633B (zh) 2025-08-12
JP2025514336A (ja) 2025-05-02
WO2023208108A1 (zh) 2023-11-02
TW202342456A (zh) 2023-11-01
EP4516781A4 (en) 2026-04-29
US20250282753A1 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
CN113717157A (zh) 用作cdk7激酶抑制剂的化合物及其应用
JP7713253B2 (ja) キサンチンオキシダーゼ抑制剤
JP2009529556A (ja) ＮＦ−κＢ阻害薬（プロテアソーム阻害薬）としてのチアゾール
RU2670088C1 (ru) Соль мангиферин-6-о-берберина, способ ее получения и применение
ES3059451T3 (en) Compound used as ret kinase inhibitor and application thereof
TWI870839B (zh) 可用於降尿酸的化合物
JP2008519049A (ja) 増殖性疾患の治療のためのｓｒｃキナーゼインヒビターおよびｂｃｒ−ａｂｌインヒビターの組み合わせ医薬
CN106957315A (zh) N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
JP2025514336A5 (https=)
WO2019020828A1 (en) NEW FUNCTIONALIZED PURINE-2,6-DIONES AND CORRESPONDING USE IN MEDICINE
CN112209886A (zh) 2-(3-氰基-4-烷氧基)苯基嘧啶衍生物及其制备方法和用途
WO2025051211A1 (zh) 用作cdk4激酶抑制剂的化合物及其应用
WO2024235218A1 (zh) Hdac1/2选择性抑制剂及其用途
TWI922802B (zh) 可用於痛風的化合物
CN116836154B (zh) 可用于痛风的化合物
CN111662239B (zh) 1,2,4-三唑类化合物及其制法和药物用途
TW201831177A (zh) 醯胺衍生物
TW202448441A (zh) 脯氨醯羥化酶抑制劑及其用途
WO2024081789A2 (en) Histone demethylase inhibitors for treating cancers
WO2025237355A1 (zh) 一种glp-1受体激动剂化合物、其制备方法及其应用
WO2025185643A1 (zh) 用作cdk4蛋白激酶抑制剂的化合物及其应用
CN121627684A (zh) 用作cdk4蛋白激酶抑制剂的化合物及其应用
HK40090211A (en) Compound used as ret kinase inhibitor and application thereof
CN114073703A (zh) 用于治疗非酒精性脂肪肝炎的组合物和方法